Avion Wealth’s Ultragenyx Pharmaceutical RARE Stock Holding History

Avion Wealth’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15	Closed	–	–	1486
2025 Q2	$0	Buy	+15	New	+$541	﹤0.01%	1528

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Avion Wealth's RARE Position: Q3 2025 in Review

Avion Wealth sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 15 shares.

Avion Wealth first reported a position in RARE in Q2 2025 and held it in 1 quarter. The position peaked at $0 in Q2 2025. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

Avion Wealth reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Avion Wealth sold 15 Ultragenyx Pharmaceutical shares in Q3 2025.
Avion Wealth first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and held it in 1 quarter.
Avion Wealth's Ultragenyx Pharmaceutical position peaked at $0 in Q2 2025.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Avion Wealth's 13F filing for Q3 2025, filed 24 Oct 2025.